(SRTS) Sensus Healthcare, Inc. Company Overview

Sensus Healthcare, Inc. is a Nasdaq-listed medical-device company, ticker SRTS, focused on non-invasive treatment of non-melanoma skin cancer and post-surgical keloid scars. Its core platform uses low-energy superficial radiotherapy, or SRT, to treat lesions at skin depth without cutting, anesthesia, sutures, or reconstructive surgery. The company’s official technology overview positions SRT as an office-based alternative for selected patients who might otherwise undergo surgery.

Where does the company sit in healthcare?

Sensus operates at the intersection of dermatology, radiation oncology, medical imaging, and reimbursement. Private dermatology practices are the main commercial entry point because they diagnose a large share of basal-cell and squamous-cell carcinomas. Radiation-oncology practices and hospitals are another channel: SRT can reserve higher-cost linear accelerators for more complex cancers. Plastic surgeons are a smaller adjacent market because the platform also has FDA clearance for keloid treatment.

The historical model was dominated by selling SRT-100, SRT-100+, and SRT-100 Vision systems. That produces substantial revenue when a unit ships and acceptance conditions are met, but it also creates volatile quarters. Sensus is now layering recurring and over-time revenue onto the installed base through service contracts, leases, revenue-sharing placements, operational support, consumables, and cloud-connected workflow tools. The 2025 Form 10-K describes this transition from a primarily equipment-sale model toward a mixed product-and-services model.

What is the Fair Deal Agreement?

Under the Fair Deal Agreement, Sensus places equipment and provides a turnkey operating package that can include a radiotherapy technologist, radiation-oncology oversight, medical-physics oversight, and workflow support. In exchange, Sensus receives a contractual percentage of SRT reimbursement collected by the practice. This lowers a customer’s upfront capital barrier and can create recurring revenue, but Sensus incurs installation and training costs before the revenue stream matures.

What did the Q1 2026 revenue mix look like?

For the quarter ended March 31, 2026, product revenue recognized at a point in time was $1.653 million; product revenue recognized over time was $0.343 million; service revenue recognized at a point in time was $0.523 million; and service revenue recognized over time was $0.875 million. The mix shows that 41.2% of quarterly revenue came from service categories, a useful signal that the installed-base strategy is becoming economically visible even while total revenue remains small.

The latest results show a company in transition rather than a smooth growth curve. In the Q1 2026 earnings release, revenue fell to $3.394 million from $8.344 million because Sensus made no direct sales to its historically largest customer and shipped fewer systems. Yet revenue excluding that customer’s prior-year contribution increased from $2.7 million, indicating partial diversification beneath the headline decline.

Why did gross margin fall?

The company’s Q1 2026 Form 10-Q also shows that two U.S. customers represented 25% and 24% of revenue, compared with one customer at 69% in Q1 2025. Concentration remains high, but it is more distributed than a year earlier.

Dedicated CPT codes for SRT and image-guided SRT became effective January 1, 2026. Sensus says the new structure increased the per-fraction delivery code by approximately 300%, improved reimbursement clarity, and strengthened practice economics. The company’s official coding announcement frames this as recognition of SRT as a standalone treatment modality.

How could reimbursement change customer behavior?

Early operating evidence is mixed but directionally relevant: Q1 2026 Fair Deal treatment volumes increased 8% year over year; 18 sites were active and 9 were pending activation at March 31, 2026. The company also launched Sensus Healthcare Financial Services, which offers purchase and leasing pathways through third-party banks. The strategic question is whether stronger inquiries convert into installations quickly enough to absorb selling costs and the upfront economics of placements.

Sensus’s current model is best understood as a sequence of shifts: from a device startup, to a public equipment seller, to a platform attempting to combine hardware, services, reimbursement participation, and connectivity.

1. 2010
   The business was organized and established its contract-manufacturing relationship, enabling product development without building a large factory base.
2. 2014
   FDA clearance for keloid treatment expanded the platform beyond skin cancer and created an adjacent clinical use case.
3. 2016
   The initial public offering gave Sensus access to equity markets and subjected the business to public-company reporting and governance requirements.
4. 2021
   Sensus achieved annual profitability for the first time, demonstrating that equipment volume could produce operating leverage.
5. 2024
   Sensus Healthcare Services was formed and the Fair Deal Agreement became the vehicle for recurring reimbursement-sharing economics.
6. 2025
   Lower purchases from the largest customer and heavy reimbursement-related spending pushed the company back to a $7.719 million net loss.
7. 2026
   Dedicated CPT codes took effect; Sensus launched financing services and Sensus Link, tying reimbursement, acquisition financing, and installed-base software into one commercial strategy.

What does Sensus Link change?

The February 2026 launch of Sensus Link adds cloud-based workflow, treatment documentation, and operating intelligence to the installed SRT-100 base. Strategically, this matters because software can make older systems more useful, support service relationships, and raise switching costs. Financially, however, the company has not yet disclosed enough revenue or retention data to treat software as a proven material stream.

Which resources are genuinely differentiated?

The strongest differentiation is the integrated office-based proposition: proprietary low-energy radiotherapy, image guidance in the Vision system, training, physics support, service, and reimbursement assistance. Sensus reported eight issued U.S. and global patents in the 2025 10-K, including hybrid imaging and workflow patents extending into 2033-2039. Contract manufacturing also reduces fixed asset intensity.

Who competes with Sensus?

Competition is broader than a list of device manufacturers. The primary substitute is Mohs and other surgery, supported by entrenched referral patterns and physician training. Other radiation technologies, electronic brachytherapy, legacy orthovoltage systems, and larger oncology-equipment providers can compete for budgets and clinical confidence. Sensus must therefore win on outcomes, patient selection, reliability, total cost, reimbursement, and practice economics—not hardware specifications alone.

Does Sensus have enough liquidity?

At March 31, 2026, Sensus had $18.327 million of cash, $42.590 million of current assets, $5.860 million of current liabilities, and no borrowings outstanding. That produces a current ratio of about 7.3x. The balance sheet therefore provides a cushion, but cash fell $3.756 million during Q1 2026 and inventory rose to $16.500 million. Inventory plus prepaid inventory totaled $18.978 million—slightly more than cash—showing how much capital is committed ahead of expected demand.

One constraint is financing access. Sensus was in default of a minimum-profitability covenant at March 31, 2026, though it had no borrowings, and the lender notified the company that the revolving facility would terminate effective May 20, 2026. The immediate balance-sheet risk is therefore not debt service; it is the combination of operating losses, inventory commitments, and the loss of an unused liquidity backstop.

Sensus has one common share class and no disclosed dual-class voting structure. Ownership is meaningful but not controlled by a single founder or sponsor. The 2026 proxy statement reported 16,462,059 shares outstanding as of April 10, 2026.

What governance signals deserve attention?

The board had six members in the 2026 proxy, with the chairman and CEO roles combined under Joseph Sardano and no lead independent director elected. The board is classified, with directors serving staggered three-year terms. Those features support continuity but can reduce the speed of governance change. The company’s governance page provides committee and policy materials. Researchers should also note that annual cash bonuses for named executives are approximately 70% objective-based, while the remainder is discretionary.

The opportunity is straightforward: dedicated reimbursement codes, an aging installed base that can be connected and serviced, third-party financing, and greater acceptance of non-surgical treatment could convert Sensus from a lumpy equipment vendor into a broader treatment platform. The risk is that the transition requires cash, customer education, operational staffing, regulatory compliance, and sustained treatment volume before recurring economics become large enough to offset fixed costs.

Which DCF drivers matter most?

A DCF for Sensus is unusually sensitive to revenue timing and margin normalization. The most important assumptions are system volumes, the percentage of customers using Fair Deal or leases, treatment utilization per active site, recurring service revenue, gross margin after installation costs, operating-expense discipline, and inventory conversion. Terminal value deserves caution because reimbursement policy, patent duration, treatment substitution, and customer concentration can change the durability of cash flows.

Sensus Healthcare matters because it is trying to change both the clinical delivery and the economics of treating non-melanoma skin cancer. Its device portfolio, image-guided workflow, 955-system installed base, reimbursement expertise, and expanding service model give it a credible platform. The 2026 CPT codes may improve physician economics at the exact moment the company is adding financing, revenue-sharing placements, and cloud connectivity.

The financial evidence is not yet conclusive. FY2025 revenue fell 34%, Q1 2026 revenue fell 59.3% year over year, gross margin dropped to 29.2%, and first-quarter operating cash use reached $3.753 million. At the same time, revenue excluding the historically largest customer improved, customer concentration became less singular, service revenue reached 41.2% of the quarterly mix, and the company retained $18.327 million of cash with no borrowings outstanding at March 31, 2026.